Private Market View

Hoya Lab

Seoul, South Korea · Privately Held (backing)

PA Mark · $/share
$187
Sep 2026
Implied valuation
Total raised
Last round

Key facts

as of Sep 2026
  • Notable investors include Tech Incubator Program for Startup, C&Venture Partners, WOW Partners.
  • 3 institutional filers report fund marks on Hoya Lab across 16 filings.
  • Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence
~$187per share
as of Sep 2026 · the exact daily mark is a member feature
Composed from 3 inputs:N-PORT marks 100%
Free account
See the evidence behind this price
  • ·The complete investor list — 3 names
  • ·Watchlist + deal alerts for Hoya Lab
  • ·The full record, as it builds
Create free account
No card required

Recorded secondary trades

No prints on record

No secondary trades in Hoya Lab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

3 filers · latest May 2026

3 SEC-registered funds reported 16 fair-value marks on Hoya Lab between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.

Funding rounds

No rounds on record

No funding rounds for Hoya Lab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Hoya Lab

Developer of an AI-driven biotechnology tool intended for precision genetic editing. The company's platform integrates computational guide design algorithms with biological validation workflows, applies predictive modeling to minimize off target effects, incorporates experimental data from unauthorized trials and ongoing institutional studies, and focuses on rare disease applications, enabling global research organizations to improve accuracy in gene therapy development, accelerate validation processes, and explore advanced approaches for addressing complex genetic disorders.

Sector
Healthcare
HQ
Seoul, South Korea
Ownership
Privately Held (backing)